Introduction
============

Basal like breast cancers (BLBC) represent between 10 and 20% of breast cancers. They are associated with an aggressive phenotype, high histological grade, poor clinical behavior, and high rates of relapse [@B1]. This cancer subgroup is characterized by lack of estrogen receptor (ER), progesterone receptor (PR), and HER2 amplification (TNBC: triple-negative breast cancers) with expression of basal cytokeratins 5/6, 14, 17, epidermal growth factor receptor (EGFR), and/or c-KIT. Currently, BLBC lack any specific targeted therapy, due to the fact that they do not express ER or HER2 and thus are typically refractory to endocrine therapy and to trastuzumab, a humanized monoclonal antibody that targets HER2.

The identification of new markers and therapeutic targets is thus necessary for this bad prognosis cancer type. First, BRCA1-associated BC are mostly BLBC [@B2] and sporadic BLBC (occurring in women without germline *BRCA1* mutations) often show dysfunction of the BRCA1 pathway. The characteristics of hereditary BRCA1-associated BC found in sporadic BLBC cancers have thus been termed «BRCA-ness» with potential clinical implications [@B3]. As BRCA1 pathway may be deficient in BLBC, these tumors may respond to specific therapeutic regimens, such as inhibitors of the poly (ADP-ribose) polymerase (PARP) enzyme [@B4]. Cells deficient in BRCA1 have indeed a defect in the repair of DNA double strand breaks which could make them particularly sensitive to the chemotherapy drugs that generate such breaks, such as inhibitors of PARP enzyme. However, not all BLBC are associated with BRCA1 inactivation.

Then, EGFR could represent a therapeutic target as it is often overexpressed in BLBC. Recently, a phase II clinical trial showed good results (57% of pathological complete response) of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer [@B5]. Nevertheless, this study highlighted biological signatures correlated with treatment response. Heterogeneity of triple negative breast cancers requires subtyping in order to better identify molecular-based therapy. In 2006 already, Neve et al. separated BLBC cell lines in two subgroup (basal A and basal B) with different invasive properties [@B6]. Lehmann et al. then identified 6 triple-negative breast cancer subtypes including 2 basal-like (BL1 and BL2), an immunomodulatory (IM), a mesenchymal (M), a mesenchymal stem-like (MSL) and a luminal androgen receptor (LAR) subtype [@B7].

All these subclassification of triple negative breast cancers were identified by studying transcriptomic profiles. Epigenetic modifications in breast cells could also allow identifying characteristics of these breast cancers. Roll et al. reported a hypermethylator phenotype in BLBC, characterized by methylation-dependent silencing of *CEACAM6, CDH1, CST6, ESR1, GNA11, MUC1, MYB, SCNN1A, and TFF3* genes that are involved in a wide range of neoplastic processes relating to tumors with poor prognosis [@B8].

Our results of Methyl-Seq did not confirm this hypermethylator phenotype but we could not identify hypermethylated BLBC specific genes. On the other hand the RNA-Seq data allowed us to identify antioxidation and cell migration as specifically activated pathways in basal-like breast cancer cells.

Materials and methods
=====================

Biological material
-------------------

The main characteristics of the cell lines used are presented in table [1](#T1){ref-type="table"}. MDA-MB-231 and HCC1937 human breast cancer cell lines were purchased from the American Type Culture Collection (Rockville, MD, USA) and were grown in RPMI medium supplemented with 10% foetal calf serum, 2 mM L-glutamine and 20 μg/ml gentamicin. SUM149 and SUM1315 human breast cancer cell lines were obtained from Asterand (Hertfordshire, UK) and grown in Ham\'s F12 medium according to the manufacturer\'s instructions. SUM1315MO2 cells were transfected with a pLXSN plasmid containing the full-length BRCA1 cDNA using Fugene 6 transfection reagent (Roche Molecular Biochemicals). Control cells were transfected with the pLXSN empty vector. After selection in 721.5 µM G418 (Sigma Aldrich), clones were tested for BRCA1 expression by Western blotting [@B9]. All cell lines were grown at 37˚C in a humidified atmosphere containing 5% CO2. All our cell lines are stored and managed by the CJP Biological Resources Center (BB-0033-00075).

Cell immunohistochemistry
-------------------------

Cells were fixed in Preservcyt solution (Thinprep) and cytoblocks were prepared with Shandon Cytoblock kit (Thermo Scientific). Hormone receptors (ER and PR), HER2, EGFR and cytokeratin status were studied as already described [@B5]. The immunostainings were scored semi-quantitatively by an expert pathologist under a light upright microscope.

Nucleic acid extraction
-----------------------

DNA extraction was performed using the QIAamp DNA mini kit (Qiagen) for cell lines and the QIAamp DNA micro kit (Qiagen) for tumors. RNA extraction was performed using RNeasy mini kit (Qiagen). The quantity and quality of the nucleic acids obtained were measured spectrophotometrically at 260nm and 280nm. RNA were also checked on 2100 Bioanalyzer (Agilent Technologies).

RNA sequencing and data processing
----------------------------------

First, mRNA were purified using Oligotex mRNA mini kit (Qiagen). cDNA libraries were then generated following the GS-FLX Titanium cDNA Rapid Library Preparation Method Manual (Roche). Finally, emPCR amplification and 454 sequencing were performed according to the manufacturer\'s protocol (emPCR Amplification Manual- Lib-L LV and Sequencing Method Manual-GS FLX Titanium Series, Roche). RNA-Seq data are available in the ArrayExpress database ([www.ebi.ac.uk/arrayexpress](http://www.ebi.ac.uk/arrayexpress)) under accession number E-MTAB-5465.

Sequence reads were aligned on the human genome (hg19) with GS Reference Mapper software (Roche) and mapped on the human exome using a home-made software named AGSA. Data was then normalized by calculating the \'reads per kilo base per million mapped reads\' (RPKM) for each gene. When the RPKM value was below the threshold of 0.3, then it was considered as background noise and replaced by zero.

Validation of gene regulation by q-RT-PCR
-----------------------------------------

Total RNAs were extracted from cell lines using RNeasy mini kit (Qiagen) according to the manufacturer\'s protocol. Quality of RNAs was checked using the 2100 BioAnalyzer (Agilent Technologies). Five microgram RNA was then reverse-transcribed using First-strand cDNA synthesis kit (GE Healthcare). Multiplex quantitative RT-PCR was performed using a 7900HT Fast Real-Time PCR System (Applied Biosystems).

Predesigned and validated gene-specific probe-based Taq-Man Gene Expression Assays were used and relative gene expression was determined using the comparative threshold cycle method. Ribosomal 18S was chosen as the endogenous control gene.

Methyl-DNA sequencing and data processing
-----------------------------------------

First, DNA was fragmented by nebulization during 1min30sec at 2.1 bar of nitrogen pressure. After DNA purification using Qiaquick PCR purification kit (Qiagen), methylated DNA was captured using MethylCap kit (Diagenode) following the supplier recommendations. Libraries were generated using GS FLX Titanium Rapid Library Preparation Kit (Roche). Finally, emPCR amplification and 454 sequencing were performed according to the manufacturer\'s protocol (emPCR Amplification Manual- Lib-L LV and Sequencing Method Manual-GS FLX Titanium Series, Roche). Methyl-Seq data are available in the ArrayExpress database ([www.ebi.ac.uk/arrayexpress](http://www.ebi.ac.uk/arrayexpress)) under accession number E-MTAB-5468.

Sequence reads were aligned on the human genome (hg19) with GS Reference Mapper software (Roche) and mapped on the human proximal promotors using a home-made software named AGSA. Data was then normalized by calculating the \'reads per million mapped reads\' (RPM) for each gene. When the RPM value was below the threshold of 0.3, then it was considered as background noise and replaced by zero.

TCGA data analysis
------------------

Both clinical and RNA sequencing data (Illumina HiSeq RNAseq Version 2 data) of invasive breast cancers were downloaded from The Cancer Genome Atlas (TCGA) database. A total of 449 patients with information on ER, PR and HER2 status were selected to compare the expression profiles of genes in the respective tumors. 71 cases were found to have a negative ER, PR end HER2 phenotype (i.e., triple-negative), whereas 371 cases were positive for at least one of these receptors.

Statistical analysis
--------------------

Statistical analysis of data was performed using R software. Significant differences between cell line groups were sought by Wilcoxon test. Statistical overrepresentation test were performed using PANTHER classification system [@B10]. For TCGA data, Student\'s *t-*test was used to assess statistical differences in mean normalized expression between triple negative and non triple negative groups. A *p*-value ≤ 0.05 was considered statistically significant.

Results
=======

Data normalization
------------------

Our transcriptome data consisted of 16,008 genes before and 13,168 genes after RPKM normalization. Methylome data consisted of 6,140 genes before and 6,109 genes after RPM normalization. Eliminated genes are those whose expression or methylation, for each cell line, did not exceed the background noise.

For the transcriptome, the average standard of each cell line data was much higher than the median and the third quartile revealing a very high concentration of data around zero and a very large number of reads for some genes as observed in the box plots (Fig [1](#F1){ref-type="fig"} and Table [2](#T2){ref-type="table"}). Regarding the methylome, median and third quartile were zero while the average was between 0.8 and 1.8 readings per gene revealing again a very high concentration of data around zero and a very large number of reads for some genes. In addition, for the transcriptome and methylome, all cell lines displayed a strong deviation above the average of the number of reads per gene. This revealed a very high dispersion of data.

From RPKM or RPM data, log normalization was performed to dilate the low values and strengthen high values. Standardization was also performed to obtain a standardized normal distribution. These two normalizations could be coupled to give reduced centered log normalized data.

Non supervised analysis
-----------------------

First we investigated how breast cancer cell lines clustered by RNA-Seq and Methyl-Seq.

For RNA-Seq, a hierarchical clustering on the RPKM normalized RNA-Seq data was generated from Euclidean distances according to Ward\'s method (Fig [2](#F2){ref-type="fig"}). This hierarchical clustering was performed for the base matrix (Fig [2](#F2){ref-type="fig"}A), the log normalized data (Fig [2](#F2){ref-type="fig"}B), the standardized data (Fig [2](#F2){ref-type="fig"}C) and the log-standardized data (Fig [2](#F2){ref-type="fig"}D). This showed that whatever the normalization, the SUM1315 lines, SB and SL are always classified together, like the two luminal T47D and MCF7 cell lines. As already observed with RNA microarrays, transcriptomic analyse by RNA-Seq thus allowed to separate luminal and basal-like breast cancer cells.

In contrast, the benign MCF10A line appears to be different from the tumor lines only for the base matrix (Fig [2](#F2){ref-type="fig"}A). This is in agreement with the fact that this cell line was classified as basal-like in several studies [@B6],[@B11].

For Metyl-seq, a hierarchical clustering on the RPM normalized Methyl-Seq data was generated from Euclidean distances according to Ward\'s method (Fig [3](#F3){ref-type="fig"}). This hierarchical clustering was performed for the base matrix (Fig [3](#F3){ref-type="fig"}A), the log normalized data (Fig [3](#F3){ref-type="fig"}B), the standardized data (Fig [3](#F3){ref-type="fig"}C) and the log-standardized data (Fig [3](#F3){ref-type="fig"}D). Metyl-seq data were neither massively influenced by breast cancer subtype nor by BRCA1 mutation. It seems like MDA231 and MDA436 present a hypermetylated phenotype. These two cell lines have thus a higher mean of methylation (1.535 and 1.343 versus 0.7 to 0.95 for all the other cell lines).

Search for genes most significantly regulated
---------------------------------------------

To determine whether the data are normally distributed, a Kolmogorov-Smirnov test was performed by taking as reference the normal distribution on basic matrix (data), normalized log (data log), centered reduced (data C & R) and centered reduced normalized log (log data C & R). For transcriptome and methylome data, the p-value was less than 2.10^-16^ for the four matrices. Thus, the p-value is very significantly lower the first degree risk α, set at 0.01. It is recognized that the data does not follow a normal distribution. Wilcoxon non-parametric statistical test was thus performed for each gene to select genes significantly regulated between two groups of cell lines.

### Subtype: 1205 genes with p\<0.05

First of all, we compared the luminal to the basal cell lines. 1205 genes were found significantly different for expression in luminal versus basal-like cell lines (p\<0.05). Among them, we found well-known basal-specific genes, such as EGFR, VIM, CAV1 and CAV2 [@B1]. Conversely, ESR1, coding for the estrogen receptor alpha, is only expressed in the two luminal cell lines. Luminal keratins (KRT8, KRT18 and KRT19) are also significantly more expressed in luminal cell lines.

For the genes used for clinical classification of basal-like breast cancers, we could compare our RNA-Seq data to immunohistochemistry results (Table [3](#T3){ref-type="table"}). A very good correlation was observed between mRNA expression analysed by RNA-Seq and protein expression studied by immunocytochemistry.

With the objective of identifying new therapeutic targets for basal-like breast cancers, we selected genes that were highly expressed (\>10 RPKM) and significantly up-regulated in basal cell lines. This reduced the list to 77 candidate genes (Table [4](#T4){ref-type="table"}). Thanks to the expression data extracted from the TCGA project \"Breast Invasive Carcinoma\", we confirmed significant overexpression for 48 genes of this list in triple negative breast tumors compared to non triple-negative breast tumors. Among them, some have already been described as basal-like markers, such as Annexin A1 [@B12],[@B13] and Vimentin [@B14],[@B15].

This 77 basal-like specific genes list was also submitted to Panther statistical overrepresentation test. Two molecular functions were given as overrepresented in this list (Fig [4](#F4){ref-type="fig"}A): antioxydant activity (5 genes, p=0.0318), and cadherin involved in cell-cell adhesions (6 genes, p=0.0231). For these 11 genes, TCGA data were compared for triple negative and non triple negative breast cancers (Fig [4](#F4){ref-type="fig"}B). Significant overexpression in triple negative breast cancers was found for SOD1, MGST3 and PRDX1 antioxydation genes and for PFN1, ITGB1, ARGLU1 and ANXA1 cadherin binding genes.

Influence of BRCA1: specific study SL / SB: 979 genes with p\<0.05
------------------------------------------------------------------

We studied our BRCA1 transfected cell lines: SL and SB come from the BRCA1 mutated SUM1315 cell line that was stably transfected with empty LXSN plasmid (SL: SUM1315-LXSN) or with a BRCA1 coding plasmid (SB: SUM1315-BRCA1). As already demonstrated [@B9], we could check that SB cell line expressed around 5 times more BRCA1 transcripts than SL cell line. Comparing these 2 cell line RNA sequencing, we found 979 genes significantly differently expressed. Among them, 304 genes were expressed at least twice more in SL comparing SB (Table [5](#T5){ref-type="table"}). This gene list was submitted to Panther statistical overrepresentation test. The molecular functions the most overrepresented included semaphorin receptor activity (5 genes, p=0.0071), growth factor binding (12 genes, p=0.00327) and cell adhesion molecule binding (21 genes, p=0.0177).

We found 9 genes that were overexpressed both in basal-like cell lines compared to luminal cell lines and in BRCA1 mutated (SL) compared to BRCA1 restored (SB) cell lines (Fig [5](#F5){ref-type="fig"}A). We performed q-RT-PCR experiments in order to validate these overexpressed genes. For 7 of these genes, we could validate higher expression in basal-like cell lines (Figure [5](#F5){ref-type="fig"}B) and in BRCA1 mutated cell line (Figure [5](#F5){ref-type="fig"}C). These 7 genes can be considered as basal-like biomarkers and potential therapeutic targets, particularly in BRCA1-mutated cancers. Above these genes, four are linked to cytoskeleton and could thus be implicated in epithelial cell migration: VIM, ITGB1, RHOA and TUBB6.

Discussion
==========

Our study tested RNA-Seq and Methyl-Seq as sensitive methods to categorize breast cancer tumor cells. We found that Methyl-Seq is not an appropriate method to differentiate breast cancer subtypes. The weak quantity of data generated with our technology is a limit that could probably be overcome with the latest generations of sequencers. Nevertheless it seems that the subtypes of breast cancers do not broadly influence genome methylation. Among the genes published by Roll et al.[@B8], only ESR1 was found to be methylated in the MDA-MB-231 and MCF10A cell lines. We also observed a specific profile of the MDA-MB-231 and MDA-MB-436 cell lines, which appear to be globally hypermethylated. Deeper study will be needed to understand why these cell lines are hypermethylated.

By contrast, RNA-Seq was proven as a reliable method for breast cancer classification. We showed that different subtypes could be separated by global gene clustering. Moreover transcript expression analyzed by RNA-Seq was shown to correlate with protein expression evaluated by immunohistochemistry. With the steady decrease in sequencing prices, RNA-Seq could become the standard method for the molecular characterization of breast tumors. This could make it possible to propose a personalized treatment according to the therapeutic targets overexpressed in the tumor.

In our study we chose to focus on basal-like breast tumors. We thus identified some potentially new targets in this breast cancer subtype. PANTHER analysis [@B10] revealed that genes involved in cadherin binding were overrepresented in the basal-like overexpressed genes. For most of them, we could confirm overexpression in triple negative breast cancers thanks to the Cancer Genome Atlas data. Among them PFN1 codes for profilin1, a regulator of actin polymerization but it is known to be downregulated in breast cancers [@B16]. In contrast, our study confirms overexpression of two genes involved in breast cancer progression, the ANXA1 and ITGB1 genes. ANXA1 was already shown to be associated with triple negative breast cancers [@B13],[@B17]. A recent study already identified ITGB1, that codes for integrin beta 1, as a potential prognosis biomarker in triple negative breast cancers [@B18].

Furthermore, genes involved in cell oxidation regulation were also found to be overexpressed in basal-like breast cancers. GPX1 codes for glutathione peroxidase 1 that protects cells against oxidative stress. A polymorphism of this gene has been associated to breast cancer risk [@B19]. The PARK7 gene (also known as DJ-1) is involved in neuron protection against oxidative stress and cell death. It was recently shown to interact with HER3 receptor [@B20]. For these two genes, our results showed at least a 3 fold overexpression in basal-like breast cancer cell lines but in TCGA triple negative breast tumors this overexpression was not confirmed. For SOD1, PRDX1 and MGST3, triple negative cell overexpression was observed both in our cell lines and in TCGA tumors. MGST3 is another gene belonging to antioxidant system shown to be overexpressed in some melanomas [@B21]. Superoxyde dismutase 1 is an enzyme coded by the gene SOD1. It has already been suggested as a potential anti-cancer drug [@B22],[@B23]. At last, PRDX1 has a controversial role in oxidization-reduction balance and its expression seems to be up-regulated in breast cancer tissues [@B24]. Oxydative stress could thus be targeted in basal-like breast cancers. This therapeutic strategy has already been proposed in other types of cancer [@B25],[@B26].

BRCA1 is a double strand break repair gene known to be frequently inactivated in basal-like breast cancers. In our results, BRCA1 mutation does not appear to influence massively the transcriptome of breast cancer cells. Nevertheless, we looked for genes overexpressed both in basal-like and in BRCA1 mutated breast cancer cells. ITGB1 is one of these genes, BRCA1 could thus be proposed as a regulator of integrin beta 1. It could be particularly interesting to inhibit ITGB1 in BRCA1 mutated basal-like breast cancers. VIM gene codes for vimentin protein, a mesenchymal marker, and we also found it overexpressed in BLBC cell lines and in BRCA1 mutated cell line. It is also an interesting biomarker of triple negative and BRCA1 mutated breast cancers. MicroRNA-138, which targets vimentin, has thus been proposed as a therapeutic agent for breast cancer [@B28]. RhoA and TUBB6 are also overexpressed in BRCA1 mutated and basal-like breast cancers. TUBB6 gene codes for a tubulin protein, the major constituent of microtubule cytoskeleton. RhoA is a small GTPase involved in actin cytoskeleton organization and it thus regulates cell shape and motility [@B27]. Physical reorganization of the cytoskeleton appears to be important in BRCA1 mutated breast cancers. This ability to remodel the cellular form could explain the high metastatic capacities of these cancers. Targeting the proteins involved in this function could thus be an effective therapeutic strategy for basal type breast cancers.

The results published here are in part based upon data generated by the TCGA Research Network: <http://cancergenome.nih.gov/>. We used the PANTHER classification system to analyze RNA-Seq data [@B10].

![**Data standardization.** The distribution of transcriptome and methylome data are represented in boxplot. For most of the cell lines, the distribution has many values ​​close to zero and a minority of extreme values.](ijmsv15p0046g001){#F1}

![**Ascending hierarchical classification of breast cancer cell line RNA-Seq data.** Classification of cell lines according to the Euclidean distances of gene expression for the basic matrix (A), log normalized (B), centered reduced (C) and log normalized and centered reduced (D).](ijmsv15p0046g002){#F2}

![**Ascending hierarchical classification of breast cancer cell line Methyl-Seq data.** Classification of cell lines according to the Euclidean distances of gene methylation for the basic matrix (A), log normalized (B), centered reduced (C) and log normalized and centered reduced (D).](ijmsv15p0046g003){#F3}

![**Expression of some genes involved in antioxydation and in cadherin binding.** A. Gene expression found in our RNA-Seq study are presented as RPKM values. For all these genes, significant overexpression was observed in triple negative cell lines. B. TCGA data are presented as RPKM values. \*\*: p \<0.01; \*\*\*: p\<0.001](ijmsv15p0046g004){#F4}

![**Expression of genes overexpressed in triple negative and in BRCA1-mutated cell lines.** A. Gene expressions found in our RNA-Seq study are presented as RPKM values. For all these genes, significant overexpression was observed both in triple negative versus luminal cell lines and in BRCA1 mutated (SL) versus BRCA1 (SB) restored cell lines. B. Gene overexpression in basal-like breast cancer cell lines was confirmed by q-RT-PCR. \*: p \<0.05 C. Gene overexpression in BRCA1 mutated (SL) compared to BRCA1 restored (SB) cell lines was confirmed by q-RT-PCR. \*: p \<0.05](ijmsv15p0046g005){#F5}

###### 

Main characteristics of the cell lines.

  Cell line            Site of origin     Pathology                       Molecular type (6)   Triple negative subtype (7)   BRCA1 status         TP53 status
  -------------------- ------------------ ------------------------------- -------------------- ----------------------------- -------------------- -------------------
  MCF10A               Normal breast      Fibrocystic                     Basal B              \-                            Wild type            Wild Type
  MCF7                 Pleural effusion   Adenocarcinoma                  Luminal              \-                            Wild type            Wild Type
  T47D                 Pleural effusion   Adenocarcinoma                  Luminal              \-                            Wild type            Missense mutation
  MDA231               Pleural effusion   Adenocarcinoma                  Basal B              MSL                           Wild type            Missense mutation
  MDA436               Pleural effusion   Adenocarcinoma                  Basal B              MSL                           5382insC             Nonsense mutation
  HCC1937              Primary tumor      Infiltrating ductal carcinoma   Basal A              BL1                           5396 + 1G\>A         Nonsense mutation
  SUM149               Primary tumor      Inflammatory breast carcinoma   Basal B              BL2                           2288delT             Missense mutation
  SUM1315              Skin metastasis    Infiltarting ductal carcinoma   Basal B              \-                            185delAG             Missense mutation
  SUM1315-LXSN (SL)    Skin metastasis    Infiltarting ductal carcinoma   Basal B              \-                            185delAG             Missense mutation
  SUM1315-BRCA1 (SB)   Skin metastasis    Infiltarting ductal carcinoma   Basal B              \-                            185delAG + sauvage   Missense mutation

###### 

Summary of transcriptome and methylome data.

                                       MCF10A    MCF7     T47D     MDA231   MDA436   HCC1937   SUM149   SUM1315   SL       SB
  -------------------------- --------- --------- -------- -------- -------- -------- --------- -------- --------- -------- ------
  **Transcriptome (RPKM)**   Mean      3.08      2.11     2.12     2.87     2.07     2.99      2.58     2.24      1.91     2.01
  Median                     0.55      0.53      0.58     0.57     0.53     0.60     0.58      0.54     0.48      0.49     
  3^rd^ quartile             1.56      1.47      1.58     1.76     1.45     1.82     1.63      1.46     1.37      1.43     
  Maximum                    1213.98   1033.06   645.80   774.17   982.73   975.89   965.45    517.51   453.00    664.35   
  Standard deviation         21.12     11.91     9.980    14.65    12.31    14.55    15.56     11.65    8.33      9.43     
  **Methylome (RPM)**        Mean      0.95      0.89     0.95     1.53     1.34     0.88      0.83     0.75      0.92     0.76
  Median                     0.00      0.00      0.00     0.00     0.00     0.00     0.00      0.00     0.00      0.00     
  3^rd^ quartile             0.00      0.00      0.00     0.00     0.00     0.00     0.00      0.00     0.00      0.00     
  Maximum                    17.56     37.71     57.87    42.33    70.12    27.30    39.14     20.69    52.60     42.95    
  Standard deviation         1.77      2.08      2.70     3.06     3.90     1.99     2.33      1.61     2.33      2.18     

Means, medians, 3rd quartile, maximum values and standard deviations of the normalized data RPKM (transcriptome) and RPM (methylome) are presented for each cell line.

###### 

Comparison of RNA-Seq and immunohistochemistry data.

            Gene    Protein   MCF10A      MCF7       T47D       MDA231      MDA436     HCC1937     SUM149      SUM1315    SL         SB
  --------- ------- --------- ----------- ---------- ---------- ----------- ---------- ----------- ----------- ---------- ---------- ----------
  RNA-Seq   ESR1    ERalpha   0           1.05       0.88       0           0          0           0           0          0          0
  IHC               ER        \-          \+ (90%)   \+ (50%)   \-          \-         \-          \-          \-         \-         \-
  RNA-Seq   PGR     PR        0           0          0.45       0           0          0           0           0          0          0
  IHC               PR        \-          \+ (40%)   \+ (80%)   \-          \-         \-          \-          \-         \-         \-
  RNA-Seq   ERBB2   HER2      0.40        1.31       0.90       0.46        0          0.43        0.36        0          0          0
  IHC               HER2      \-          \-         \-         \-          \-         \-          \-          \-         \-         \-
  RNA-Seq   KRT5    CK5       148.0       0          0          0           0          11.7        6.3         0          0          0
  KRT6A     CK6     102.9     0           0          0          0           0.8        8.2         0           0          0          
  KRT6B     CK6     6.8       0           0          0          0           0          5.1         0           0          0          
  KRT6C     CK6     3.7       0           0          0          0           0.3        2.4         0           0          0          
  IHC               CK5/6     \+ (90%)    \-         \-         \-          \-         \+ (25%)    \+ (25%)    \-         \-         \-
  RNA-Seq   KRT14   CK14      76.1        0          0          0.3         0          5.5         0.4         0          0          0
  IHC               CK14      \+ (80%)    \-         \-         \-          \-         \+ (20%)    \+ (\<1%)   \-         \-         \-
  RNA-Seq   EGFR    EGFR      0.90        0          0          0.88        0.82       0.50        1.22        0.44       0.51       0.62
  IHC               EGFR      \+ (100%)   \-         \+ (40%)   \+ (100%)   \+ (90%)   \+ (100%)   \+ (100%)   \+ (90%)   \+ (60%)   \+ (80%)

RNA-Seq results are presented as RPKM values. Results of immunohistochemistry are presented as negative (-) or positive (+), specifying the percentage of labeled cells.

IHC: immunohistochemistry; ER: estrogen receptor; PR: progesteron receptor; CK: cytokeratin.

###### 

List of the 77 genes highly expressed and significantly up-regulated in basal-like breast cancer cell lines.

                      MCF7    T47D    MCF10A   MDA231   HCC1937   MDA436   SUM149   SUM1315   SL       SB
  ------------------- ------- ------- -------- -------- --------- -------- -------- --------- -------- --------
  MIR198              0       14,19   93,95    774,17   975,89    982,74   814,74   517,52    82,52    70,38
  UQCRHL ^\#^         58,16   77,51   430,89   182,15   184,14    222,29   352,09   412,39    223,07   181,27
  TMSB10 ^\#^         25,42   9,40    150,63   508,74   111,48    85,40    215,62   244,01    142,27   192,18
  PFN1 ^\#^           77,62   79,56   152,67   276,20   206,92    233,86   257,91   111,56    137,20   122,80
  S100A6 ^\#^         22,98   19,45   416,84   181,76   87,12     197,18   213,62   134,53    77,28    78,92
  MIR638              24,28   25,53   56,63    163,59   310,95    27,49    26,78    37,29     45,69    43,01
  S100A2 \*^\#^       0       0       396,33   1,83     6,93      1,03     58,95    13,39     12,77    4,03
  LGALS1 ^\#^         4,33    8,97    94,73    31,84    40,83     66,74    88,92    76,64     45,56    35,35
  MRPL51 ^\#^         9,48    6,10    33,88    40,25    83,61     53,47    79,59    53,90     43,90    33,53
  GADD45G IP1 ^\#^    20,21   13,10   56,25    46,81    46,27     52,13    54,98    61,42     49,41    44,08
  VIM \*^\#^          0,50    0       4,16     66,68    0,77      45,39    5,55     92,39     111,79   57,37
  GBA3 ^\#^           23,01   13,33   38,60    63,11    41,76     26,47    47,50    44,67     42,65    43,55
  SF3B5 ^\#^          21,57   11,73   60,91    26,86    30,75     65,28    22,73    44,05     40,86    47,65
  C12orf57            15,12   3,36    19,90    44,05    39,11     16,08    70,09    62,27     34,24    25,15
  SOD1                12,50   18,37   28,37    32,57    32,45     43,47    32,28    40,60     32,88    41,36
  SEP15               4,65    4,20    18,88    68,50    88,43     12,53    22,00    23,38     15,92    20,07
  RHOA \*             18,08   15,94   31,02    23,71    34,34     31,11    30,49    39,17     42,33    26,96
  ANXA1 ^\#^          0       0,74    28,25    48,48    68,29     32,67    23,70    21,05     15,59    19,83
  CTSL1               2,72    1,46    8,66     5,45     11,97     42,06    7,19     97,48     35,75    48,36
  SEC61G ^\#^         6,17    9,31    31,31    15,74    25,86     25,40    28,09    55,55     18,64    22,24
  PRKCDBP ^\#^        0       0       12,95    110,28   58,21     1,48     16,03    5,36      5,97     11,87
  GPX1                0       0       45,87    21,07    56,00     26,42    32,33    6,82      13,15    10,05
  CAV1                0       0       19,90    9,06     11,40     12,18    8,70     62,73     35,85    44,37
  MIR548G             7,94    0       17,20    54,05    17,83     23,58    26,84    20,86     19,93    19,37
  IGFBP3 ^\#^         0       0       0,52     3,06     35,62     5,03     0,42     7,23      71,32    72,54
  MRPL18 ^\#^         11,32   10,28   20,14    25,41    31,24     22,67    22,04    25,26     23,32    21,50
  TOMM5 ^\#^          5,41    8,71    22,67    37,90    32,04     23,64    10,35    24,73     13,88    17,39
  NOL7 ^\#^           5,33    8,45    10,25    27,78    22,53     8,94     11,42    42,43     28,90    29,18
  NCL ^\#^            12,21   12,21   18,56    20,20    12,60     40,10    20,97    24,80     20,65    20,23
  LOC100134713 ^\#^   1,05    0,40    45,26    32,04    38,63     13,57    5,78     18,77     12,09    9,76
  MIR221              0       0       22,90    18,12    16,71     20,65    22,83    31,35     12,88    30,41
  DRAP1               4,31    5,40    8,48     50,74    53,09     9,56     12,60    10,83     10,24    10,17
  PRNP ^\#^           3,60    4,94    26,82    31,78    39,99     6,25     19,82    15,22     6,41     15,54
  SNX3 \*^\#^         7,77    4,94    20,69    25,26    40,09     23,57    10,62    17,08     13,86    9,34
  GADD45A \*          0,78    1,59    8,91     31,59    32,62     17,73    2,67     20,19     27,45    12,92
  TM4SF1 ^\#^         0,51    0       3,27     37,44    25,03     6,81     9,97     26,03     18,67    26,40
  MRPL34 ^\#^         12,20   11,19   29,64    19,45    19,31     18,26    15,31    18,10     13,49    18,97
  MANF \*^\#^         3,78    4,36    8,94     52,26    30,04     8,20     13,00    13,69     16,19    8,36
  PRDX1 ^\#^          7,42    6,62    15,43    8,62     20,45     16,24    21,76    21,97     19,50    26,71
  MLF2 ^\#^           9,78    7,32    13,41    13,15    26,36     20,47    23,37    16,44     19,19    16,94
  C17orf89 ^\#^       4,00    5,19    13,21    32,82    51,74     7,74     12,94    8,25      8,05     11,30
  PARK7               4,73    9,46    17,09    28,64    29,03     11,81    23,99    12,18     10,79    12,07
  NDUFA1              3,53    3,62    27,60    31,00    16,17     15,70    17,73    22,27     5,95     7,62
  WBP5 ^\#^           0       1,76    9,72     42,26    11,18     31,02    4,59     20,00     15,79    9,17
  MRPS33              9,14    9,83    34,59    11,75    17,39     17,43    16,19    13,81     15,79    10,16
  EEF1E1 ^\#^         4,18    5,29    15,98    41,85    24,68     12,12    20,58    7,80      5,37     8,01
  EBNA1BP2 ^\#^       3,20    7,18    9,58     23,10    18,68     10,83    9,71     17,32     26,00    16,38
  TGFBI ^\#^          0       0       14,00    0,36     1,69      0,98     7,18     28,45     25,45    53,07
  TIMMDC1             4,62    4,31    7,56     9,96     45,53     14,17    12,67    16,41     6,67     8,83
  SSBP1 ^\#^          4,59    4,44    22,03    17,02    17,64     12,73    7,92     17,30     12,90    11,92
  NDUFA6              4,88    6,14    22,30    13,72    20,13     15,85    15,91    16,97     7,08     7,03
  DEGS1               3,71    2,40    15,70    17,47    14,80     9,62     24,47    13,43     7,90     14,16
  POMP                4,66    4,53    14,31    15,16    18,07     6,27     14,01    18,71     14,00    15,72
  FAM96B ^\#^         2,86    2,49    7,98     20,27    37,20     3,58     15,76    9,45      14,00    7,22
  CNIH4               2,38    2,70    25,54    24,52    15,68     5,42     25,05    5,20      5,07     4,73
  TUBB6\*^\#^         3,22    3,14    11,60    31,30    6,52      4,95     6,54     14,02     20,88    14,37
  MGST3 ^\#^          2,93    3,59    28,31    6,61     13,63     12,62    10,69    14,69     12,31    10,71
  MRPL50              5,92    4,35    15,89    7,48     19,59     9,21     13,52    18,73     13,84    10,01
  EMP3                1,18    0,71    2,53     23,75    12,14     8,89     5,89     20,73     17,77    14,68
  ITGB1 \*            1,71    3,11    3,24     12,42    13,20     5,08     6,81     27,43     21,63    12,56
  CAPG ^\#^           0,44    2,72    16,12    24,80    14,30     8,38     10,00    12,28     9,43     6,45
  ARGLU1              5,76    4,22    12,54    14,83    23,04     11,06    13,22    9,79      6,34     10,58
  NOP16 ^\#^          7,04    3,55    17,47    11,58    11,93     11,64    11,67    17,28     9,52     10,16
  HIST1H2BC           0       0       1,29     0,73     3,72      1,72     4,59     43,46     21,81    22,94
  UQCR11              5,03    2,05    43,52    7,93     6,62      6,19     8,99     10,77     6,97     8,51
  VKORC1L1            3,51    4,51    6,73     20,57    35,75     10,50    7,37     6,23      4,62     6,97
  MRPS15 ^\#^         3,55    4,53    15,28    8,90     16,47     8,13     11,86    11,24     12,77    12,19
  UBA52 ^\#^          4,68    3,17    18,72    8,21     8,33      11,36    14,47    17,47     8,43     8,56
  MRPS6 ^\#^          1,55    3,25    10,22    6,78     4,26      8,21     16,38    26,15     9,38     12,48
  TRAPPC3 ^\#^        5,10    4,38    11,16    13,86    11,94     7,53     9,19     14,14     13,21    12,60
  SSU72 ^\#^          7,68    7,17    12,52    13,80    15,57     7,80     8,45     11,33     10,31    11,90
  RBX1 ^\#^           1,51    1,99    8,76     22,44    22,06     7,59     9,59     10,66     2,05     3,22
  COTL1 ^\#^          2,13    2,15    4,19     5,45     20,06     13,86    6,97     9,80      10,02    13,43
  DDT ^\#^            3,88    4,63    29,74    5,75     6,53      5,77     9,57     9,91      7,70     8,61
  RPS12 ^\#^          4,11    3,59    17,47    7,04     8,50      9,25     9,52     14,96     8,63     7,79
  NOP56 ^\#^          3,23    4,49    7,52     20,87    19,58     7,55     8,79     4,96      5,14     7,90
  PRPS1L1\*           1,96    1,96    4,26     19,40    9,97      16,52    4,43     4,97      14,80    6,06

RNA-Seq results are presented as RPKM values.

\* : genes that are also significantly overexpressed in BRCA1 mutated (SL) compared to BRCA1 restored (SB) cell lines.

**^\#^**: genes that are significantly overexpressed in triple negative breast cancers in the TCGA RNAseq data.

###### 

List of the 304 genes significantly up-regulated in BRCA1 mutated cell line (SL) compared to BRCA1 wild-type cell line (SB).

                 SL       SB                       SL        SB
  -------------- -------- ------- -- ------------- --------- --------
  PPP1R13B       0.480    0.000      PROCR         6.688     1.963
  F2RL1          2.620    0.000      UPP1          1.905     0.561
  PAX8           0.830    0.000      TADA3         3.076     0.906
  FBXL16         0.910    0.000      FURIN         3.987     1.184
  F2R            0.750    0.000      ZNF337        1.604     0.479
  UBE2D1         0.660    0.000      TDP1          1.103     0.331
  UBASH3B        0.900    0.000      SAC3D1        2.500     0.750
  SMYD4          0.550    0.000      ZBED4         2.813     0.854
  DBNDD2         1.540    0.000      RFWD3         3.386     1.030
  S1PR1          2.750    0.000      ACTR8         1.420     0.442
  PLXNB1         0.240    0.000      ZNF467        1.333     0.417
  CDC42EP3       4.000    0.000      ATG7          1.053     0.331
  DLX5           1.200    0.000      RAB11A        7.800     2.500
  PLAGL2         2.620    0.000      LEO1          2.505     0.806
  TMEM164        0.360    0.000      PTPN23        1.141     0.369
  SLC25A20       0.610    0.000      CPT1A         1.714     0.560
  MRE11A         0.260    0.000      TRIP11        1.221     0.399
  FLRT2          2.000    0.000      CRTC3         0.659     0.217
  LOC101448202   0.980    0.000      ENO2          2.669     0.882
  NR1I3          0.910    0.000      RPLP1         14.833    4.938
  SOX9           1.750    0.000      ZNF346        0.875     0.292
  PSTK           0.680    0.000      FAM72D        1.000     0.333
  HOXB9          1.120    0.000      GSE1          1.125     0.377
  SPP1           1.000    0.000      EFTUD1        1.548     0.522
  NOV            1.140    0.000      PTPN1         1.518     0.513
  FAM173A        0.970    0.000      TCF7          1.475     0.500
  DACT1          1.060    0.000      CSTB          21.750    7.417
  SQRDL          1.040    0.000      PRSS23        10.250    3.500
  PRSS12         0.440    0.000      SEC22C        1.535     0.526
  SERPINE2       1.020    0.000      SNAPC1        2.508     0.863
  CIB2           0.970    0.000      TGFB2         1.280     0.442
  NHLRC2         0.310    0.000      ZDHHC9        1.146     0.396
  LMBRD1         0.570    0.000      PPP1R13L      1.224     0.424
  SORT1          0.710    0.000      PINX1         1.670     0.583
  AKAP12         1.650    0.000      TOR1A         4.850     1.700
  RGS4           1.880    0.000      FEM1B         6.750     2.375
  CACNG7         1.140    0.000      DDAH1         1.058     0.375
  ANKRD50        1.480    0.000      SORBS3        3.436     1.222
  THBS1          0.980    0.000      TGFB1         3.345     1.190
  KRTAP2-3       3.250    0.000      LASP1         1.970     0.702
  FGF5           7.750    0.000      C11orf71      3.500     1.250
  PCCA           0.288    0.000      PALM2-AKAP2   1.069     0.383
  LAMB3          0.318    0.000      VAT1          4.042     1.450
  RAD51D         1.058    0.000      MBOAT2        0.972     0.350
  MMD            0.300    0.000      PDZD8         1.621     0.588
  EVA1A          2.000    0.000      GPC1          2.712     0.994
  PLA2G16        1.125    0.000      ZFC3H1        0.919     0.337
  GTDC2          2.750    0.000      GTF2A2        5.250     1.938
  IQCC           0.838    0.000      ZNF410        2.091     0.772
  TCAIM          0.546    0.000      TMEM126B      3.375     1.250
  DCLRE1C        0.854    0.000      TMEM5         2.675     0.992
  NUP210         0.394    0.000      TRAPPC6B      1.225     0.458
  SLC38A6        0.482    0.000      ZFR           1.473     0.552
  EEF1A2         1.529    0.000      MDM2          1.375     0.517
  PODXL          6.777    0.167      GOLPH3        2.542     0.958
  SIX1           3.000    0.125      NINJ1         1.875     0.708
  RAD18          0.879    0.050      TNNT1         2.757     1.048
  BAK1           1.458    0.083      USP4          1.222     0.464
  ATP5O          1.167    0.083      TRIP13        1.326     0.504
  SPOCK1         1.079    0.083      LRIG1         0.539     0.205
  FXYD5          1.217    0.100      ALDH5A1       2.469     0.948
  ZNF12          1.500    0.125      CSTF2T        3.250     1.250
  SLC19A2        1.700    0.150      CHCHD3        1.263     0.488
  HOXC10         1.375    0.125      SIN3A         3.334     1.293
  TAGLN          3.167    0.292      FIBP          2.121     0.826
  TSR2           1.333    0.125      TSC22D4       1.708     0.667
  GEMIN2         0.521    0.050      GINS1         2.704     1.063
  FNDC1          1.734    0.167      CD9           12.719    5.000
  TAF3           0.646    0.063      HYAL2         2.000     0.792
  FAN1           0.831    0.083      GNA13         3.938     1.563
  ADCK1          1.417    0.143      FLNB          1.526     0.606
  TMOD3          2.295    0.250      ABHD6         0.942     0.375
  RYBP           1.708    0.188      EZR-AS1       6.250     2.500
  CTSH           0.567    0.063      NBEAL2        0.646     0.258
  RAB27A         0.750    0.083      KIF7          1.077     0.431
  FAM174A        1.125    0.125      YME1L1        5.181     2.073
  ZBTB47         0.742    0.083      NAP1L1        2.651     1.063
  ALOX12B        1.104    0.125      SRP54         2.849     1.149
  ITPKC          0.521    0.063      SEL1L         1.385     0.559
  CLP1           1.000    0.125      SEC23A        3.282     1.325
  GCSH           1.292    0.167      EAPP          2.067     0.838
  ZDHHC3         1.746    0.229      TTC8          1.029     0.418
  MST4           0.750    0.100      TAF1D         1.963     0.800
  FAM102A        1.369    0.188      IKBIP         5.313     2.167
  MORC4          0.876    0.121      IDH2          2.602     1.064
  HSBP1          2.958    0.417      NUDT5         0.958     0.400
  STC1           10.625   1.500      RALY          6.750     2.821
  ATE1           1.598    0.226      VIM           118.611   49.583
  ZNF672         1.750    0.250      PHF7          0.893     0.375
  UFD1L          0.575    0.083      SVIL          1.001     0.421
  CTNNBIP1       5.083    0.750      MET           2.561     1.084
  PMEPA1         0.833    0.125      TGFBR2        2.798     1.185
  RAB8B          0.883    0.133      SMARCC1       1.714     0.733
  TDRKH          0.960    0.146      ROCK1         0.875     0.375
  TK2            1.092    0.167      NFATC3        1.302     0.558
  FHL1           0.792    0.125      RRP1B         3.012     1.303
  PTPN2          1.467    0.244      NUDT21        6.107     2.643
  RAB13          2.646    0.458      SEC13         4.444     1.929
  HDAC9          0.713    0.125      LARP6         7.625     3.313
  ATP1A3         0.225    0.042      ANP32B        2.036     0.887
  ZNF529         0.875    0.167      TPX2          8.578     3.813
  OCIAD2         2.833    0.542      KIF5B         5.363     2.392
  RAP1GAP2       1.389    0.266      DHCR24        2.361     1.054
  RAB5A          3.104    0.604      ZC3H14        2.023     0.903
  TTLL5          0.736    0.144      NPC2          7.950     3.550
  S100A2         5.625    1.125      UNC45A        4.306     1.924
  DEDD           3.063    0.625      NHLRC3        0.838     0.375
  SIMC1          0.700    0.146      TRPC4AP       3.223     1.450
  RPSA           4.771    1.000      ATP6V0A2      0.702     0.317
  COMMD7         2.185    0.467      APEX2         2.196     0.992
  SH3KBP1        1.694    0.371      FBXO34        4.417     2.000
  SPTLC2         1.413    0.313      TERF2IP       8.083     3.667
  TMEM251        3.375    0.750      RINT1         1.524     0.692
  SRPX           2.377    0.533      SUPV3L1       1.802     0.821
  EIF1AD         1.479    0.333      UBP1          2.618     1.196
  ASNA1          5.226    1.192      DARS2         1.533     0.708
  THAP10         2.375    0.542      HSD17B11      1.730     0.800
  PPP3CC         0.770    0.179      MEX3B         8.375     3.875
  ZKSCAN1        1.063    0.250      KIFC3         1.531     0.710
  PLXDC1         1.908    0.458      SMC2          1.902     0.883
  TSPAN31        1.342    0.325      DDX18         2.071     0.962
  PTPRF          3.353    0.813      ZBTB5         1.792     0.833
  TMED10         4.875    1.188      POLG          2.531     1.177
  UXT            1.188    0.292      SNUPN         3.223     1.500
  DYNLRB1        4.292    1.063      MFGE8         1.527     0.714
  WSB2           1.963    0.492      CNOT10        1.595     0.746
  UBXN2A         0.729    0.183      ATG4B         0.851     0.400
  VTI1B          2.292    0.583      SLC30A6       1.250     0.590
  ITPR3          2.743    0.707      UBR7          1.366     0.650
  RAB39B         3.375    0.875      RAB1A         5.250     2.500
  SS18           0.864    0.225      REEP4         2.141     1.021
  SLC2A1         2.184    0.579      PGM3          1.866     0.890
  CTGF           14.850   3.950      STYX          1.004     0.479
  PRKACA         3.103    0.825      PKM           52.114    24.886
  PRPS1L1        7.500    2.000      AGPAT2        2.267     1.083
  PIP4K2A        1.003    0.271      QRICH1        3.250     1.558
  ITPK1          1.982    0.536      CENPN         2.008     0.964
  ELK1           2.125    0.575      BRD3          1.119     0.539
  PWWP2A         1.375    0.375      SLC38A1       1.973     0.955
  RAC1           4.458    1.217      RARS          2.777     1.344
  SMC5           0.835    0.228      MYBL2         1.482     0.718
  RAB18          3.279    0.905      PPM1G         7.431     3.600
  BAHD1          1.075    0.300      RPL27A        3.508     1.700
  ZBTB1          6.208    1.750      HDGFRP3       5.250     2.550
  EPC1           0.990    0.281      AQR           0.596     0.292
  VPS18          0.950    0.271      GADD45A       15.313    7.500
  CHMP2B         1.833    0.525      QARS          2.197     1.089
  RANBP10        1.012    0.292      NRP1          1.489     0.738
  KIF3B          2.313    0.667      KIF23         4.444     2.208
  PUSL1          1.292    0.375      HK1           3.444     1.713
  ADAM19         1.526    0.444      SNX3          9.000     4.500
  GORAB          1.708    0.500      TRAK1         2.001     1.001

RNA-Seq results are presented as RPKM values.
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